The Warburg effect then and now: From cancer to inflammatory diseases

BioEssays

Volumn 35, Issue 11, 2013, Pages 965-973

  Palsson Mcdermott, Eva M ^a   O'Neill, Luke A J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Glycolysis; Hif 1 ; Inflammation; Metabolism; PKM2; TLR; Warburg effect

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIHYDROXYACETONE PHOSPHATE; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR; PATTERN RECOGNITION RECEPTOR; PYRUVATE DEHYDROGENASE KINASE; PYRUVIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUCCINIC ACID;

ADAPTIVE IMMUNITY; AMINO ACID SYNTHESIS; ARTICLE; BIOSYNTHESIS; CITRIC ACID CYCLE; DENDRITIC CELL; GLYCOLYSIS; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY DISEASE; INNATE IMMUNITY; LIPOGENESIS; MACROPHAGE; METABOLISM; NEOPLASM; PATHOGENESIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WARBURG EFFECT;

GLYCOLYSIS; HIF-1Α; INFLAMMATION; METABOLISM; PKM2; TLR; WARBURG EFFECT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CITRIC ACID; CITRIC ACID CYCLE; DENDRITIC CELLS; GLYCOLYSIS; HEXOKINASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNITY, INNATE; INFLAMMATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MEMBRANE PROTEINS; METABOLIC NETWORKS AND PATHWAYS; MITOCHONDRIA; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SUCCINIC ACID; THYROID HORMONES; TRANSCRIPTION FACTORS;

EID: 84885377829     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201300084     Document Type: Article

References (73)

1. Warburg O. 1923. Metabolism of tumours. Biochem Z 142: 317-33.
2. Koppenol WH, Bounds PL, Dang CV. 2011. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11: 325-37.
3. Warburg O. 1925. Iron, the oxygen-carrier of respiration-ferment. Science 61: 575-82.
4. Racker E. 1972. Bioenergetics and the problem of tumor growth. Am Sci 60: 56-63.
5. Turner JS, Brittain EG. 1962. Oxygen as a factor in photosynthesis. Biol Rev Camb Philos Soc 37: 130-70.
6. Larbi A, Zelba H, Goldeck D, Pawelec G. 2010. Induction of HIF-1alpha and the glycolytic pathway alters apoptotic and differentiation profiles of activated human T cells. J Leukoc Biol 87: 265-73.
7. Denko NC. 2008. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8: 705-13.
8. Maynard MA, Ohh M. 2007. The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 64: 2170-80.
9. Darekar S, Georgiou K, Yurchenko M, Yenamandra SP, et al. 2012. Epstein-Barr virus immortalization of human B-cells leads to stabilization of hypoxia-induced factor 1 alpha, congruent with the Warburg effect. PLoS One 7: e42072.
10. Kondo K, Klco J, Nakamura E, Lechpammer M, et al. 2002. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-46.
11. Semenza GL. 2010. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-34.
12. Shi LZ, Wang R, Huang G, Vogel P, et al. 2011. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med 208: 1367-76.
13. Garedew A, Henderson SO, Moncada S. 2010. Activated macrophages utilize glycolytic ATP to maintain mitochondrial membrane potential and prevent apoptotic cell death. Cell Death Differ 17: 1540-50.
14. Krawczyk CM, Holowka T, Sun J, Blagih J, et al. 2010. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 115: 4742-9.
15. Dinarello CA, Simon A, van der Meer JW. 2012. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11: 633-52.
16. West AP, Brodsky IE, Rahner C, Woo DK, et al. 2011. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature 472: 476-80.
17. Infantino V, Convertini P, Cucci L, Panaro MA, et al. 2011. The mitochondrial citrate carrier: a new player in inflammation. Biochem J 438: 433-6.
18. O'Neill LA. 2011. A critical role for citrate metabolism in LPS signalling. Biochem J 438: e5-6.
19. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, et al. 2005. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7: 77-85.
20. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, et al. 2013. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 496: 238-42.
21. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. 2006. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metabol 3: 177-85.
22. Lu CW, Lin SC, Chen KF, Lai YY, et al. 2008. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 283: 28106-14.
23. Papandreou I, Cairns RA, Fontana L, Lim AL, et al. 2006. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabol 3: 187-97.
24. Zhang Z, Tan M, Xie Z, Dai L, et al. 2011. Identification of lysine succinylation as a new post-translational modification. Nat Chem Biol 7: 58-63.
25. Du J, Zhou Y, Su X, Yu JJ, et al. 2011. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334: 806-9.
26. Rubic T, Lametschwandtner G, Jost S, Hinteregger S, et al. 2008. Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. Nat Immunol 9: 1261-9.
27. Sadagopan N, Li W, Roberds SL, Major T, et al. 2007. Circulating succinate is elevated in rodent models of hypertension and metabolic disease. Am J Hypertens 20: 1209-15.
28. Rotstein OD, Pruett TL, Fiegel VD, Nelson RD, et al. 1985. Succinic acid, a metabolic by-product of Bacteroides species, inhibits polymorphonuclear leukocyte function. Infect Immun 48: 402-8.
29. Kurebayashi Y, Nagai S, Ikejiri A, Koyasu S. 2013. Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes Cells 18: 247-65.
30. Mayne CG, Williams CB. 2013. Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm Bowel Dis
31. Ishikawa D, Okazawa A, Corridoni D, Jia LG, et al. 2013. Tregs are dysfunctional in vivo in a spontaneous murine model of Crohn's disease. Mucosal Immunol 6: 267-75.
32. Miyara M, Sakaguchi S. 2011. Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns. Immunol Cell Biol 89: 346-51.
33. O'Neill LA, Hardie DG. 2013. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 493: 346-55.
34. Dang EV, Barbi J, Yang HY, Jinasena D, et al. 2011. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146: 772-84.
35. Vamecq J, Colet JM, Vanden Eynde JJ, Briand G, et al. 2012. PPARs: interference with Warburg' effect and clinical anticancer trials. PPAR Res 2012: 304760.
36. Zhao Y, Liu H, Riker AI, Fodstad O, et al. 2011. Emerging metabolic targets in cancer therapy. Front Biosci 16: 1844-60.
37. Jiang L, Deberardinis RJ. 2012. Cancer metabolism: when more is less. Nature 489: 511-2.
38. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, et al. 2008. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-3.
39. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95.
40. Tamada M, Suematsu M, Saya H. 2012. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells. Clin Cancer Res 18: 5554-61.
41. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, et al. 2010. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329: 1492-9.
42. Sun Q, Chen X, Ma J, Peng H, et al. 2011. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 108: 4129-34.
43. Yang W, Zheng Y, Xia Y, Ji H, et al. 2012. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol 14: 1295-304.
44. Pouyssegur J, Dayan F, Mazure NM. 2006. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-43.
45. Gao X, Wang H, Yang JJ, Chen J, et al. 2013. Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals. J Biol Chem 288: 15971-9.
46. Gao X, Wang H, Yang JJ, Liu X, et al. 2012. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell 45: 598-609.
47. Luo W, Hu H, Chang R, Zhong J, et al. 2011. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145: 732-44.
48. Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, et al. 2012. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol 8: 839-47.
49. Sutendra G, Michelakis ED. 2013. Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol 3: 38.
50. Vary TC. 1991. Increased pyruvate dehydrogenase kinase activity in response to sepsis. Am J Physiol 260: E669-74.
51. Sanchez-Arago M, Chamorro M, Cuezva JM. 2010. Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis 31: 567-76.
52. Cao W, Yacoub S, Shiverick KT, Namiki K, et al. 2008. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 68: 1223-31.
53. Wong JY, Huggins GS, Debidda M, Munshi NC, et al. 2008. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 109: 394-402.
54. Sun RC, Fadia M, Dahlstrom JE, Parish CR, et al. 2010. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 120: 253-60.
55. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, et al. 2002. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 105: 244-50.
56. Stacpoole PW, Nagaraja NV, Hutson AD. 2003. Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 43: 683-91.
57. Ojuka EO. 2004. Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc Nutr Soc 63: 275-8.
58. Merrill GF, Kurth EJ, Hardie DG, Winder WW. 1997. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 273: E1107-2.
59. Winder WW, Holmes BF, Rubink DS, Jensen EB, et al. 2000. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 88: 2219-26.
60. Dandapani M, Hardie DG. 2013. AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells? Biochem Soc Trans 41: 687-93.
61. Pilon G, Dallaire P, Marette A. 2004. Inhibition of inducible nitric-oxide synthase by activators of AMP-activated protein kinase: a new mechanism of action of insulin-sensitizing drugs. J Biol Chem 279: 20767-74.
62. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, et al. 2012. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336: 918-22.
63. Lee HM, Kim JJ, Kim HJ, Shong M, et al. 2013. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 62: 194-204.
64. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F, 2010. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9: 1092-9.
65. Hong J, Zhang Y, Lai S, Lv A, et al. 2013. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 36: 1304-11.
66. Gou S, Cui P, Li X, Shi P, et al. 2013. Low concentrations of metformin selectively inhibit CD133(+) cell proliferation in pancreatic cancer and have anticancer action. PLoS ONE 8: e63969.
67. Pierotti MA, Berrino F, Gariboldi M, Melani C, et al. 2013. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 32: 1475-87.
68. Park CS, Bang BR, Kwon HS, Moon KA, et al. 2012. Metformin reduces airway inflammation and remodeling via activation of AMP-activated protein kinase. Biochem Pharmacol 84: 1660-70.
69. Nath N, Khan M, Paintlia MK, Singh I, et al. 2009. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol 182: 8005-14.
70. Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carnero C, et al. 2012. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med 209: 2441-53.
71. Cho DC, Hutson TE, Samlowski W, Sportelli P, et al. 2012. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer 118: 6055-62.
72. Bukowski RM. 2012. Temsirolimus: a safety and efficacy review. Expert Opin Drug Saf 11: 861-79.
73. Luo W, Semenza GL. 2011. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2: 551-6.